Papachristou Lab
Principal Investigator: Georgios I Papachristou
Institution: The Ohio State University (Columbus, OH)
Primary Subfield: Molecular & Cell Bio
Recruitment Status: Inquire for rotation/fellowship opportunities
Research Focus
PROJECT SUMMARY/Abstract Acute pancreatitis (AP) accounts for over 300,000 admissions in the U.S. with annual costs exceeding $3 billion. Most cases of AP are mild (MAP) with a hospital stay of 3-4 days, but approximately 15% of AP subjects develop severe disease (SAP), defined by presence of persistent organ failure. Up to a third of SAP patients expire from multi-system organ failure after weeks in the intensive care unit. To date, no therapeutic agents have been successful at ameliorating the protracted hospital course of SAP. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) workshops identified two critical knowledge gaps as barriers to developing pharmacologic interventions: 1) the establishment of a highly accurate, early prediction tool to identify which subjects will develop SAP during hospitalization; 2) a more in-depth knowledge of SAP mechanistic pathways and immuno-pathogenesis to identify novel therapeutic targets. We propose the MoSAIC Study (iMmune SIgnAtures and ClIniCal outcomes in AP), a prospective multi-center, observational cohort that will address both of these knowledge gaps in SAP. We recently discovered a novel multi-cytokine pan…
Active NIH Awards
- 5R01DK134698-04: Immune Signatures and Clinical Outcomes in Acute Pancreatitis (2026)
- 5U01DK127388-07: Epidemiology and Pathophysiology of Acute Pancreatitis-related Diabetes Mellitus (2026)
- 2U01DK127388-06: Epidemiology and Pathophysiology of Acute Pancreatitis-related Diabetes Mellitus (2025)
- 5R01DK134698-03: Immune Signatures and Clinical Outcomes in Acute Pancreatitis (2025)
- 5R01DK134698-02: Immune Signatures and Clinical Outcomes in Acute Pancreatitis (2024)
Explore 700+ US Biology Labs on FindBioLabs.com